242 related articles for article (PubMed ID: 31876844)
1. Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis.
Yip RML; Yim CW
J Clin Rheumatol; 2021 Dec; 27(8):e516-e524. PubMed ID: 31876844
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR
Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
Genovese MC; Burmester GR; Hagino O; Thangavelu K; Iglesias-Rodriguez M; John GS; González-Gay MA; Mandrup-Poulsen T; Fleischmann R
Arthritis Res Ther; 2020 Sep; 22(1):206. PubMed ID: 32907617
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
[TBL] [Abstract][Full Text] [Related]
5. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
6. Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis.
Maioli G; Caporali R; Favalli EG
Expert Opin Drug Discov; 2022 Aug; 17(8):799-813. PubMed ID: 35757853
[TBL] [Abstract][Full Text] [Related]
7. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
Woodworth TG; den Broeder AA
Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
[TBL] [Abstract][Full Text] [Related]
12. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
13. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
[No Abstract] [Full Text] [Related]
14. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.
Lamb YN; Deeks ED
Drugs; 2018 Jun; 78(9):929-940. PubMed ID: 29931592
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
Bouajina E; Zakraoui L; Kchir M; Kochbati S; Baklouti S
Clin Rheumatol; 2020 May; 39(5):1449-1455. PubMed ID: 31838637
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
17. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
[TBL] [Abstract][Full Text] [Related]
18. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study.
Mueller RB; Graninger W; Sidiropoulos P; Goger C; von Kempis J
Clin Rheumatol; 2017 Oct; 36(10):2187-2192. PubMed ID: 28776300
[TBL] [Abstract][Full Text] [Related]
19. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.
Buckley F; Finckh A; Huizinga TW; Dejonckheere F; Jansen JP
J Manag Care Spec Pharm; 2015 May; 21(5):409-23. PubMed ID: 25943002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
